Absent From Cancer Drugs, Glaxo Signals a Revival With New Hire

Bookmark
(Bloomberg) -- GlaxoSmithKline Plc sold its portfolio of cancer therapies almost three years ago. The drug giant’s new head of research and development looks set to rebuild.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.